By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Dyax Corp. 

55 Network Drive

Burlington  Massachusetts  01803  U.S.A.
Phone: 617-225-2500 Fax: 617-225-2501


Founded in 1995, Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key areas of focus are the KALBITOR® (ecallantide) business and the Angioedema Portfolio, as well as the Licensing and Funded Research Program (LFRP).

Dyax discovered and developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside of the United States, the Company has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and is evaluating opportunities in others. Currently, Dyax has collaboration agreements for regions including Europe, Japan, Russia, the Middle East, Australia and New Zealand. Dyax is also exploring other potential indications for KALBITOR, either alone or through collaborations.

The Company is expanding its portfolio for the treatment of angioedemas by identifying diagnostic strategies to assist in the differentiation between histamine-mediated and plasma kallikrein (bradykinin) mediated (PKM) angioedema, and developing a fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, which could be a candidate to prophylactically treat PKM angioedemas.

KALBITOR and DX-2930 were identified using Dyax’s patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 11 product candidates in various stages of clinical development, including three in Phase 3 trials.

Dyax is headquartered in Burlington, Massachusetts. For online information about Dyax Corp., please visit

Key Statistics

Ownership: Public

Web Site: Dyax Corp.
Employees: 120
Symbol: DYAX



CMIC Co., Ltd.  Ecallantide in HAE and other angioedemas indications

Sigma-Tau Group  Ecallantide in HAE and other therapeutic indications

Eli Lilly  Antibody phage display

Amgen  Antibody phage display

Merrimack  Antibody phage display

Sanofi-Aventis (New Jersey)  Antibody phage display

Biogen  Antibody phage display

Sanofi Genzyme  Hereditary Angioedema

Company News
Dyax Corp. (DYAX) Receives Positive Opinion For Orphan Medicinal Product Designation In The European Union For DX-2930 For The Treatment Of Hereditary Angioedema 9/30/2015 11:50:56 AM
Dyax Corp. (DYAX) To Participate In The Leerink Partners 4th Annual Rare Disease Roundtable 9/22/2015 10:42:47 AM
Dyax Corp. (DYAX) To Participate In The Morgan Stanley Global Healthcare Conference 9/2/2015 10:42:24 AM
Dyax Corp. (DYAX) Provides Update On DX-2930 Clinical And Commercial Supply Initiatives 8/12/2015 9:54:25 AM
Dyax Corp. (DYAX) To Participate In The 2015 Wedbush PacGrow Healthcare Conference 8/6/2015 12:19:08 PM
Dyax Corp. (DYAX) Announces Second Quarter 2015 Financial Results 7/30/2015 12:59:26 PM
Dyax Corp. (DYAX) To Host Second Quarter 2015 Earnings Call And Webcast 7/15/2015 10:08:45 AM
Dyax Corp. (DYAX) Receives FDA Breakthrough Therapy Designation For DX-2930 For Prevention Of Attacks Of Hereditary Angioedema 7/7/2015 10:26:51 AM
FDA Bestows Breakthrough Therapy Designation on Dyax Corp. (DYAX)'s HAE Drug As Suitors Circle 7/7/2015 6:01:54 AM
Alexion (ALXN), BioMarin (BMRN), Sanofi (SAN.PA), Shire (SHPGY) May Be Eyeing Dyax Corp. (DYAX) and Its Rare Genetic Disorder Drug 6/11/2015 6:27:19 AM